CN Mobile Logo


HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

The attainment of “no evidence of disease” after treatment for metastatic breast cancer is significantly associated with prolonged survival, according to a new study.

Adding pertuzumab to first-line therapy for HER2-positive breast cancer has been shown to yield a survival benefit, but a new analysis says adding the drug is not cost effective.

The presence of the truncated form of human epidermal growth factor receptor 2 (p95HER2) in circulating tumor cells is associated with poor survival in breast cancer patients.

Both chemotherapy and anti-HER2 therapy can improve survival in HER2-positive breast cancer patients with brain metastases who undergo whole-brain radiotherapy.

Breast cancer patients with PIK3CA gene mutations may not benefit from dual anti-HER2 inhibition, according to a new study in The Oncologist.

Using a novel imaging technique, researchers have discovered that differences in HER2 homodimers on breast cancer cells may point toward functional differences, with possible implications for metastasis and drug resistance.

[18F]FDG-PET/CT could predict response in patients with metastatic HER2-positive breast cancer treated with lapatinib plus trastuzumab.


Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.